ImmunityBio, Inc.
ImmunityBio Approves 2023 Executive Bonuses and Amends Code of Ethics
Summary
On February 22, 2024, ImmunityBio, Inc. approved discretionary cash bonuses for its named executive officers, with Dr. Patrick Soon-Shiong receiving $232,875, Richard Adcock $298,500, and David Sachs $273,980. The Company also granted option awards and restricted stock units to its NEOs under the 2024 Long-Term Incentive Program. Additionally, the Board of Directors approved a revised Code of Business Conduct and Ethics, enhancing provisions related to fair dealing and compliance with healthcare laws.
Profitelligence Alerts
Get alerts for IBRX
Be first to know when ImmunityBio, Inc. files with the SEC.
Filing Categories
Advertisement
About ImmunityBio, Inc.
ImmunityBio, Inc. is a pioneering biotechnology company that focuses on developing innovative immunotherapies to treat cancer and other serious diseases. The company's primary function is to leverage the body's immune system to fight against various forms of cancer as well as infectious diseases through a robust pipeline of therapies. ImmunityBio's notable features include its expansive portfolio of next-generation therapies that incorporate cutting-edge technologies, such as the NANT Cancer Vaccine and Anktiva, which are designed to enhance the immune system's natural ability to identify and eradicate tumor cells. The company plays a critical role in the healthcare and biotechnology sectors, contributing to advancements in personalized medicine and potentially transformative treatments. Headquartered in California, ImmunityBio is strategically placed in the biotechnology hub of the United States, allowing it to effectively collaborate with key players in research and clinical development. Its work is significant in the market as it represents the ongoing shift towards immunotherapy as a front-line treatment for cancer, promising to impact patient outcomes and the future of cancer care.
Official SEC Documents
Advertisement